Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

41.53
-0.8300-1.96%
Post-market: 41.530.00000.00%19:55 EDT
Volume:1.76M
Turnover:73.64M
Market Cap:10.79B
PE:14.94
High:42.70
Open:42.36
Low:41.49
Close:42.36
52wk High:49.62
52wk Low:32.38
Shares:259.71M
Float Shares:223.00M
Volume Ratio:0.57
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):2.78
ROE:35.53%
ROA:19.27%
PB:4.99
PE(LYR):14.94

Loading ...

Barclays Keeps Their Hold Rating on Exelixis (EXEL)

TIPRANKS
·
Nov 05, 2025

U.S. RESEARCH ROUNDUP-ADM, Pinterest, UL Solutions

Reuters
·
Nov 05, 2025

Exelixis (EXEL): Is There More Value Left After Recent Growth?

Simply Wall St.
·
Nov 05, 2025

BRIEF-Exelixis Inc - Authorizes $750 Million Stock Repurchase By 2026 - SEC Filing

Reuters
·
Nov 05, 2025

Exelixis Announces $750 Million Stock Repurchase Program

TIPRANKS
·
Nov 05, 2025

Exelixis Q3 Non-GAAP Earnings, Revenue Increase

MT Newswires Live
·
Nov 05, 2025

Exelixis Inc - Authorizes $750 Mln Stock Repurchase by 2026 - SEC Filing

THOMSON REUTERS
·
Nov 05, 2025

Exelixis Reports Third Quarter Revenues of $597.8 Million

Reuters
·
Nov 05, 2025

Exelixis Q3 Adjusted EPS USD 0.78 VS. Ibes Estimate USD 0.61

THOMSON REUTERS
·
Nov 05, 2025

Exelixis Inc Outlook FY Net Product Revenues $2.10 Bln - $2.15 Bln

THOMSON REUTERS
·
Nov 05, 2025

Exelixis Outlook FY Revenue USD 2,300-2,350 Million

THOMSON REUTERS
·
Nov 05, 2025

Exelixis Shares Fall After Guggenheim Downgrade

MT Newswires Live
·
Nov 04, 2025

Truist Financial Sticks to Its Buy Rating for Exelixis (EXEL)

TIPRANKS
·
Nov 04, 2025

Exelixis Cut to Neutral From Buy by Guggenheim

Dow Jones
·
Nov 04, 2025

Guggenheim Downgrades Exelixis to Neutral From Buy

MT Newswires Live
·
Nov 03, 2025

Exelixis downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
Nov 03, 2025

Exelixis Inc expected to post earnings of 61 cents a share - Earnings Preview

Reuters
·
Nov 01, 2025

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL)

TIPRANKS
·
Oct 31, 2025

Could Exelixis (EXEL) Pipeline Progress Signal a Turning Point for Revenue Diversification?

Simply Wall St.
·
Oct 29, 2025

Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics

TIPRANKS
·
Oct 28, 2025